Articles by Jane Wan - BioPharm International

ADVERTISEMENT

ADVERTISEMENT

Articles by Jane Wan

Healthcare Reform in China

Chinese healthcare reforms may be a double-edged sword for foreign companies.
Sep 1, 2014

Chinese healthcare reforms may be a double-edged sword for foreign companies.

Brunei's Potential Pharmaceutical Market Growth

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.
Jun 1, 2014

Brunei harnesses its rich biodiversity and the growing halal market in a bid to develop its pharmaceutical sector.

Regulators Get Tough on Corruption in China

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.
Mar 1, 2014

China's regulatory and compliance environment is set to change as the government declares a crackdown on bribery scandals.

Clinical Trials Head East to Asia

Companies remain optimistic about the clinical-trials industry in Asia despite its challenges.
Dec 1, 2013

The rising cost of drug development and the decreasing proportion of drug-naive population in the US and European markets are driving international pharmaceutical companies to consider emerging markets as a location to conduct their clinical trials. Asia stands out among the emerging markets given its double-digit growth rates.

Report from Myanmar

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.
Oct 1, 2013

Foreign companies zero in on Myanmar with the hope of securing a foothold in its pharmaceutical market.

Report from India

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.
Aug 1, 2013

Industry players brace themselves to face challenges as India's new drug-pricing policy kicks in full gear.

Report from Thailand

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.
Apr 1, 2013

The Thai government is ramping up efforts to promote and develop the biotechnology sector in a bid to enhance its global competitiveness.

Report from India

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.
Feb 1, 2013

India's biopharmaceutical industry is valued at $2 billion a year with 20 companies producing biosimilars and 50 products available in the domestic market.

Report from South Korea

The South Korean market is characterized by its aging population and an affluent population. Growth potential is limited as it has evolved to a developed market and industry players expect it to have established regulations.
Dec 1, 2012

The South Korean market is characterized by its aging population and an affluent population. Growth potential is limited as it has evolved to a developed market and industry players expect it to have established regulations.

ADVERTISEMENT

ADVERTISEMENT

Click here